Remibrutinib in chronic spontaneous urticaria: 52-Week results from two phase 3 studies

Journal:

The Journal of Allergy and Clinical Immunology

Published:

2025-10-19

DOI:

10.1016/j.jaci.2025.09.028

Affiliations:

23

Authors:

22

Go to article

Institutions	Authors	Share
Novartis, Switzerland	4.000000	0.18
Novartis Pharmaceuticals Corporation, United States of America (USA)	1.000000	0.05
University of Toronto (U of T), Canada	1.000000	0.05
Saint George Clinic, France	1.000000	0.05
Novo Nordisk Pharma Ltd., Japan	1.000000	0.05
Hiroshima City Hiroshima Citizens Hospital, Japan	1.000000	0.05
Dermatology Hospital, SMU, China	1.000000	0.05
Allergy and Clinical Immunology Associates, United States of America (USA)	1.000000	0.05
Endeavor Health, United States of America (USA)	1.000000	0.05
Państwowy Instytut Medyczny MSWiA, Poland	1.000000	0.05
Allergy, Asthma and Immunology Associates, Ltd., United States of America (USA)	1.000000	0.05
Aydın Adnan Menderes University (ADU), Turkey	1.000000	0.05
Novartis Ireland Ltd., Ireland	1.000000	0.05
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.000000	0.05
Novartis Biomedical Research, China	1.000000	0.05
McMaster University, Canada	0.500000	0.02
Allergy Research Canada Inc., Canada	0.500000	0.02
Charité - University Medicine Berlin, Germany	0.500000	0.02
Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Germany	0.500000	0.02
Hospital del Mar Medical Research Institute (IMIM), Spain	0.500000	0.02
Pompeu Fabra University (UPF), Spain	0.500000	0.02
Johns Hopkins Medicine (JHM), JHU, United States of America (USA)	0.500000	0.02
Johns Hopkins Bayview Medical Center, United States of America (USA)	0.500000	0.02

Interested in Clinical Sciences?